Therefore, an important future direction in anti-cancer therapeutics is the combination of metabolic therapy, VEGF/VEGFR inhibitor, immunotherapy and DNMTi; however, this strategy needs to consider the complexity and heterogeneity of the TME. Here, KDR is linked to cancer.